Jennifer L. Bishop - Search Results

Year	Number of Results
2003	1
2005	1
2006	3
2007	3
2008	3
2009	1
2013	1
2014	4
2015	5
2016	2
2017	2
2018	2
2019	1
2022	0

1

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A. Bishop JL, et al. Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26. Cancer Discov. 2017. PMID: 27784708

2

Salmonella: from pathogenesis to therapeutics.

Boyle EC, Bishop JL, Grassl GA, Finlay BB. Boyle EC, et al. Among authors: bishop jl. J Bacteriol. 2007 Mar;189(5):1489-95. doi: 10.1128/JB.01730-06. Epub 2006 Dec 22. J Bacteriol. 2007. PMID: 17189373 Free PMC article. Review. No abstract available.

3

Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.

Bishop JL, Davies A, Ketola K, Zoubeidi A. Bishop JL, et al. Endocr Relat Cancer. 2015 Jun;22(3):R165-82. doi: 10.1530/ERC-15-0137. Epub 2015 May 1. Endocr Relat Cancer. 2015. PMID: 25934687 Review.

4

PEG10 is associated with treatment-induced neuroendocrine prostate cancer.

Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A. Kim S, et al. Among authors: bishop jl. J Mol Endocrinol. 2019 Jul 1;63(1):39-49. doi: 10.1530/JME-18-0226. J Mol Endocrinol. 2019. PMID: 31013476

5

Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.

Miyahira AK, Kissick HT, Bishop JL, Takeda DY, Barbieri CE, Simons JW, Pienta KJ, Soule HR. Miyahira AK, et al. Among authors: bishop jl. Prostate. 2015 Mar 1;75(4):337-47. doi: 10.1002/pros.22920. Epub 2014 Oct 30. Prostate. 2015. PMID: 25358693 Review.

6

Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.

Thaper D, Vahid S, Kaur R, Kumar S, Nouruzi S, Bishop JL, Johansson M, Zoubeidi A. Thaper D, et al. Among authors: bishop jl. Sci Rep. 2018 Nov 23;8(1):17307. doi: 10.1038/s41598-018-35612-z. Sci Rep. 2018. PMID: 30470788 Free PMC article.

7

Effects of a compression garment on sensory feedback transmission in the human upper limb.

Barss TS, Pearcey GEP, Munro B, Bishop JL, Zehr EP. Barss TS, et al. Among authors: bishop jl. J Neurophysiol. 2018 Jul 1;120(1):186-195. doi: 10.1152/jn.00581.2017. Epub 2018 Apr 11. J Neurophysiol. 2018. PMID: 29641310 Free PMC article.

8

Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.

Ketola K, Munuganti RSN, Davies A, Nip KM, Bishop JL, Zoubeidi A. Ketola K, et al. Among authors: bishop jl. Clin Cancer Res. 2017 Nov 15;23(22):6923-6933. doi: 10.1158/1078-0432.CCR-17-0901. Epub 2017 Sep 12. Clin Cancer Res. 2017. PMID: 28899970

9

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.

Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A. Bishop JL, et al. Oncotarget. 2015 Jan 1;6(1):234-42. doi: 10.18632/oncotarget.2703. Oncotarget. 2015. PMID: 25428917 Free PMC article.

10

Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.

Vahid S, Thaper D, Gibson KF, Bishop JL, Zoubeidi A. Vahid S, et al. Among authors: bishop jl. Sci Rep. 2016 Aug 24;6:31842. doi: 10.1038/srep31842. Sci Rep. 2016. PMID: 27555231 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results